FY2025 · ended Dec 31, 2025 · Revenue $12.14M, +73.4% YoY · Filed Mar 10, 2026
Prelude Therapeutics Inc (PRLD) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $12.1 million and a net loss of $99.5 million. Free cash flow was -$56.4 million. As of Jun 30, 2026 it held $151.8 million in cash and investments and $17.6 million in total debt.
Revenue
$12.14M
+73.4% vs prior year
Net income (TTM)
$-60.49M
+51.3% vs year-ago TTM
Operating cash flow (TTM)
$-33.26M
+69.3% vs year-ago TTM
Free cash flow (TTM)
$-33.26M
+69.4% vs year-ago TTM
EPS (TTM)
$-0.72
+56.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
63.00M
+14.2% vs prior year
Net cash
$134.11M
as of Jun 30, 2026
Operating margin
-861.3%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PRLD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmington, DE
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1678660
- Former names
- Prelude Therapeutics Inc. (until Oct 20, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $12.1M | $7.0M | — | — | — |
| Operating income | -$104.6M | -$139.7M | -$132.3M | -$123.5M | -$113.7M |
| Net income | -$99.5M | -$127.2M | -$121.8M | -$115.4M | -$111.7M |
| Diluted EPS | -$1.29 | -$1.68 | -$2.02 | -$2.44 | — |
| Operating cash flow | -$56.3M | -$102.9M | -$107.1M | -$83.7M | -$83.5M |
| Free cash flow | -$56.4M | -$103.7M | -$110.6M | -$86.7M | -$85.9M |
| Total assets | $141.3M | $175.5M | $277.7M | $220.5M | $305.1M |
| Total liabilities | $72.7M | $44.1M | $40.6M | $25.1M | $19.2M |
| Stockholders' equity | $68.6M | $131.5M | $237.1M | $195.4M | $285.9M |
| Cash and investments | $103.2M | $133.6M | $232.9M | $201.7M | $291.2M |
| Total debt | $17.8M | $18.0M | $16.9M | $1.8M | $1.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 10, 2026 | Sep 10, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2026 | Jun 9, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 12, 2026 | May 12, 2026 |
All 389 Prelude Therapeutics Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.